News

16

Mar, 2021

ZIKAHOST study shares findings on genetic predisposition to typical ZIKA effects at SEIP 2021

Tags: , ,

The ZIKAHOST study aims to describe the Zika virus (ZIKV) infection taking into account the host, in this case humans, instead of the pathogen, which would be the zika virus, and we search for biomarkers of the increased likelihood of developing the disease, diagnosis and prognosis through a genomic approach. What this means is that we look at DNA to see if we could understand if patients can be genetically predisposed to develop typical ZIKV effects. The study analysed 80 DNA samples from 40 mother and child pairs. The mothers […]

READ MORE

12

Mar, 2021

Sharing our understanding of the immune response of children living with HIV

Tags: , , ,

EPIICAL is proud to have presented four abstracts at the CROI conference this year, sharing updated information on viral decay and the immune response of children living with HIV who begin treatment early in life.   EFFECT OF HIV ON IMMUNE ACTIVATION AND EXHAUSTION IN CD4 AND CD8 T CELLS IN INFANTS Stefano Rinaldi, Vinh B. Dinh, Suresh Pallikkuth, Lesley D. Armas, Nadia Sitoe, Rajendra Pahwa, Nicola Cotugno, Paula Vaz, Paolo Palma, MariaGrazia Lain, Savita G. Pahwa DYNAMICS OF INTACT PROVIRAL SEQUENCES IN EARLY TREATED HIV-1 CLADE C–INFECTED INFANTS Catherine […]

READ MORE

11

Mar, 2021

GAP-f webinar on Best practices in clinical research for the development of paediatric formulations

Tags:

We are pleased to invite you to the kick-off of #BetterDrugs4Kids, GAP-f’s new quarterly webinar series on paediatric drug optimization, featuring deep dives on paediatric drug prioritization, evaluation, development, and delivery, and promoting discussions to close the paediatric treatment gaps. The first webinar, on “Best practices in clinical research for the development of paediatric formulations”, is hosted by GAP-f’s Clinical Research Working Group, led by Penta. The webinar will be an opportunity to reflect on concrete innovations for optimizing efforts and more rapidly generate the evidence needed to inform the […]

READ MORE

11

Mar, 2021

ODYSSEY trial finds new drug is better for treating children living with HIV

Tags: , , ,

The anti-HIV drug Dolutegravir improves outcomes for children with HIV infection when given in a 3-drug combination. These results come from the ODYSSEY trial which was presented yesterday at the Conference on Retroviruses and Opportunistic Infections. Dolutegravir has a number of potential advantages, including: Few drug-to-drug interactions, making it easier to use when treating people who need treatment for other conditions such as tuberculosis High potency at a low milligram dose, meaning tablets can be small High genetic barrier to resistance Low cost Trials of dolutegravir in combination treatments in […]

READ MORE

4

Mar, 2021

International Workshop on HIV Pediatrics now accepting abstracts!

 

The 13th international workshop on HIV Pediatrics will be held virtually on 16 July 2021. Researchers from around the world are invited to submit their abstracts for presentation on one of the following topics: The workshop will feature a wide range of exciting talks, discussions, debates, clinical case presentations, and networking opportunities. Investigators at all career stages are encouraged to submit one or more abstracts. Pediatric HIV Case Finding (Including Early Infant Diagnosis) Treatment of Pediatric HIV Infection Optimising Care of Children and Youth Co-Infections/Complications of HIV/Treatment in Children and […]

READ MORE

29

Jan, 2021

Farewell to a great man

 

Penta joins our colleagues across the world in mourning the passing of our friend and research collaborator, Professor James Hakim, who died on 26 January 2021 from COVID-19 complications. He will be greatly missed by all those who had the privilege of knowing him. Professor Hakim was a prominent figure and pathfinder in the field of TB, HIV/AIDS and clinical research in Africa and his passing comes at a time where the importance of bringing HIV to the forefront has never been more significant for the world’s ability to achieve [...]
READ MORE

26

Jan, 2021

Prof. Timo Vesikari talks to us about COVID-19 vaccines and children

Tags: , ,

In December 2020 Penta held its annual Scientific Meeting. Despite the unusual get together due to COVID-19, we shared great science together. Among the experts invited was Timo Vesikari, a vaccine specialist who provided an insightful overview of the current scenario around COVID-19 vaccine development. He agreed to an interview with us and shed some light on our understanding of COVID-19 vaccines and how they impact children. Read the interview here

READ MORE
Antimicrobial Resistance

21

Jan, 2021

Speeding up the development and approvals of new antibiotics for children

Tags:

In these difficult times, it is important to remain focused on improving outcomes for children with serious multidrug-resistant infections globally. Antimicrobial Resistance (AMR) represents a substantial threat to the Sustainable Development Goals (SDGs), with a large impact on the health of children worldwide. However, there is quieter limelight on the growing threat of AMR to child health. Carlo Giaquinto, Emmanuel Roilides,  Irja Lutsar, and Mike Sharland – members of Penta ID Network, along with other international researchers have published an article to highlight this issue and call for clear steps […]

READ MORE
NEWSLETTER

We would like to update you on our recent activities